F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described hypoxia inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for treatment of ulcerative colitis and Crohn’s disease.
Ipsen SA picked up U.S. FDA accelerated approval for its Genfit SA-licensed elafibranor, making it the first new drug in eight years for treating primary biliary cholangitis, though a potential competitor lurks just around the corner.
Syntis Bio Inc. has announced its launch, with a focus on advancing a pipeline of oral therapies engineered for optimization in the small intestine and a portfolio of enzyme replacement therapies to treat orphan metabolic and broad digestive disorders.
Throughout the 2024 annual congress of the European Association for the Study of the Liver (EASL), held in Milan last week, almost all basic tracks included some reference to epigenetics, or changes to the chromatin that affect how accessible a gene is to the transcription machinery.
In metabolic dysfunction-associated steatohepatitis (MASH) preclinical models, absence of the lipid droplet-associated protein hydroxysteroid 17β dehydrogenase 13 (17β-HSD13) has been identified as protective against liver fibrosis.
The ongoing European Association for the Study of the Liver 2024 congress in Milan opened yesterday with several presentations on cell plasticity and its role in liver function and regeneration in chronic liver disease situations.
Molecular diagnostics company Genetic Signatures Ltd. is gearing up to launch its Easyscreen gastrointestinal parasite detection kit in the U.S. following its first FDA 510(k) clearance.
Epiendo Pharmaceuticals ehf and Alveolix AG have achieved significant milestones in their collaboration to advance the treatment of ulcerative colitis.
Concurrent infection with hepatitis B virus (HBV) and hepatitis delta virus (HDV) may lead to cirrhosis, fulminant hepatitis or hepatocellular carcinoma faster than infection with HBV alone.
The persistence of hepatitis B virus (HBV) covalently closed-circular DNA (cccDNA) and integration of HBV DNA into the hepatocytes lead to chronic HBV infection. Current therapies achieve long-term viral suppression but, as HBV cccDNA is not eradicated, lifelong treatment is needed.
RSS
